Get the Stockscreener App
8.05
0.98%
-0.08
After Hours:
8.10
0.05
+0.62%
Neogenomics Inc stock is traded at $8.05, with a volume of 958.36K.
It is down -0.98% in the last 24 hours and down -11.73% over the past month.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
See More
Previous Close:
$8.13
Open:
$8.074
24h Volume:
958.36K
Relative Volume:
0.49
Market Cap:
$990.95M
Revenue:
$628.25M
Net Income/Loss:
$-78.55M
P/E Ratio:
-12.98
EPS:
-0.62
Net Cash Flow:
$-29.73M
1W Performance:
+4.55%
1M Performance:
-11.73%
6M Performance:
-48.95%
1Y Performance:
-48.06%
1-Day Range:
$7.985
$8.28
1-Week Range:
$7.3967
$8.305
52-Week Range:
$6.08
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
8.05 | 990.95M | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
403.13 | 159.89B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.73 | 142.45B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
491.70 | 37.95B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
106.93 | 30.97B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
148.99 | 26.72B | 15.50B | 1.33B | 2.16B | 7.34 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-13-25 | Downgrade | The Benchmark Company | Buy → Hold |
| Dec-10-24 | Initiated | Jefferies | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-01-23 | Upgrade | Needham | Hold → Buy |
| Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-22-22 | Downgrade | Needham | Buy → Hold |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-18-22 | Resumed | Stephens | Overweight |
| Dec-16-21 | Initiated | Cowen | Outperform |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-25-21 | Resumed | Needham | Buy |
| Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-28-21 | Initiated | Truist | Buy |
| Dec-11-20 | Resumed | BTIG Research | Buy |
| Oct-28-20 | Reiterated | Needham | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Aug-28-20 | Initiated | Guggenheim | Buy |
| Jul-29-20 | Reiterated | Needham | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Buy |
| Apr-21-20 | Resumed | Stephens | Overweight |
| Mar-02-20 | Resumed | Craig Hallum | Buy |
| Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-01-19 | Reiterated | Needham | Buy |
| Mar-29-19 | Reiterated | Needham | Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Aug-21-18 | Initiated | Leerink Partners | Outperform |
| May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-24-17 | Initiated | Gabelli & Co | Buy |
| Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
Insider Buying: Stephen Kanovsky Acquires Shares of NeoGenomics Inc (NEO) - GuruFocus
NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in oncology using the UG 100 sequencing platform - Select Science
Insider Buying: Neil Gunn Acquires Shares of NeoGenomics Inc (NE - GuruFocus
Assessing NeoGenomics: Insights From 9 Financial Analysts - Benzinga
Piper Sandler Lowers Price Target on NeoGenomics (NEO) to $12.00 | NEO Stock News - GuruFocus
It's Not Too Late to Jump on These Under-the-Radar Momentum Plays - Investing.com
It's Not Too Late to Jump on These Under-the-Radar Momentum Plays - MarketBeat
NeoGenomics (NEO) Receives Adjusted Price Target from Piper Sand - GuruFocus
NeoGenomics (NEO) Receives Adjusted Price Target from Piper Sandler | NEO Stock News - GuruFocus
NeoGenomics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
How to Take Advantage of moves in (NEO) - news.stocktradersdaily.com
Press Release Distribution & PR Platform - ACCESS Newswire
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2025 Earnings Call Transcript - MSN
NeoGenomics (NEO) Price Target Lowered by Morgan Stanley | NEO S - GuruFocus
NeoGenomics (NEO) Price Target Lowered by Morgan Stanley | NEO Stock News - GuruFocus
NeoGenomics Repays $201.3 Million Convertible Senior Notes - marketscreener.com
NeoGenomics price target lowered to $10 from $17 at Morgan Stanley - Yahoo Finance
NeoGenomics clears $201.25M convertible debt ahead of maturity By Investing.com - Investing.com India
NeoGenomics clears $201.25M convertible debt ahead of maturity - Investing.com
NeoGenomics Pays Off 1.25% Convertible Senior Notes - Yahoo Finance
NeoGenomics (NEO) Shares Drop After Disappointing Q1 Revenue Rep - GuruFocus
NeoGenomics targets 25% annual NGS growth with new product launches in 2025 - MSN
NeoGenomics (NEO) Stock Target Reduced by Morgan Stanley Amid Q1 - GuruFocus
Leerink Partners Downgrades NeoGenomics (BMV:NEO) - Nasdaq
NeoGenomics (NEO) Faces Price Target Cut Amid Significant Sellof - GuruFocus
NeoGenomics (NEO) Faces Price Target Reduction Amid Sales Challe - GuruFocus
NeoGenomics (NEO) Price Target Cut by BTIG Amid Revenue Concerns - GuruFocus
NeoGenomics stock hits 52-week low at $6.25 amid market challenges - Investing.com India
NeoGenomics Q1 Earnings: The Stock Price Drop Is A Gift (Rating Upgrade) (NEO) - Seeking Alpha
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform - BioSpace
NeoGenomics Reports Strong Q1 2025 Performance - TipRanks
NeoGenomics (NEO) Kicks Off 2025 with Strong Revenue Momentum | - GuruFocus
NeoGenomics: Q1 Earnings Snapshot - MySA
NeoGenomics Reports Strong Q1 2025 Earnings Growth - TipRanks
NeoGenomics Q1 2025 Earnings Call Transcript - MarketBeat
NeoGenomics (NEO) Downgraded Amid Growth Concerns | NEO Stock Ne - GuruFocus
Why NeoGenomics (NEO) Stock Is Nosediving - MSN
Health Care Stocks Rise As Pfizer And AstraZeneca Lead Gains - Finimize
Fort Myers-based NeoGenomics posts $26M net loss in Q1 - Gulfshore Business
Earnings call transcript: NeoGenomics Q1 2025 revenue misses forecast, stock drops - Investing.com Nigeria
NeoGenomics drops as sequential revenue decline leads to Q1 miss - MSN
NeoGenomics stock drops on Q1 miss (NEO:NASDAQ) - Seeking Alpha
NeoGenomics Q1 2025 Financial Results: Sales Growth Amid Profitability ChallengesNews and Statistics - IndexBox
NeoGenomics Reports First Quarter 2025 Results - BioSpace
NeoGenomics and Ultima Genomics collaborate to expand clinical t - GuruFocus
NeoGenomics Inc (NEO) Q1 2025 Earnings: EPS of -$0.20 Beats Esti - GuruFocus
NeoGenomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
NeoGenomics Posts Q1 Breakeven Adjusted Earnings as Revenue Rises; 2025 Guidance Updated - marketscreener.com
NeoGenomics falls after Q1 sales miss - TradingView
NEO Updates FY25 Guidance Following Pathline Acquisition | NEO S - GuruFocus
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):